Brown Advisory’s “Large-Cap Growth Strategy” returned -0.88% in Q3 2025, underperforming the Russell 1000 Growth Index. The portfolio has significant AI exposure but was hindered by its underweight in speculative momentum-driven trades. Check out the fund’s top five holdings for insights into its best picks in 2025.

West Pharmaceutical Services, Inc. (NYSE: WST) was highlighted in Brown Advisory’s Q3 2025 investor letter. The stock, which designs, manufactures, and sells drug containment and delivery systems, saw a one-month return of 3.26% and a 10.65% loss over the past year. As of December 03, 2025, WST closed at $284.31 per share with a market cap of $18.554 billion.

West Pharmaceutical Services, Inc. (NYSE: WST) rebounded in Q3 2025, following strong earnings and new CFO appointment. The stock surged 20%, driven by consecutive revenue growth in high-value product segment amid easing inventory destocking headwinds.

49 hedge fund portfolios held West Pharmaceutical Services, Inc. (NYSE: WST) in Q3 2025, up from 46 in the previous quarter. The company reported $805 million in revenues, up 5% organically. While it shows investment potential, some AI stocks offer better risk-reward profiles. Explore our report on an undervalued AI stock poised to benefit from current trends.

Read more at Yahoo Finance: West Pharmaceutical Services (WST) Rebounded in Q3